Dr Mariano H Demiguel, MD | |
4235 Secor Rd, Toledo, OH 43623-4231 | |
(419) 479-5529 | |
Not Available |
Full Name | Dr Mariano H Demiguel |
---|---|
Gender | Male |
Speciality | Nephrology |
Experience | 41 Years |
Location | 4235 Secor Rd, Toledo, Ohio |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1750388435 | NPI | - | NPPES |
2167819 | Medicaid | OH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RN0300X | Internal Medicine - Nephrology | 35076290 (Ohio) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Davita - Flower Dialysis | Sylvania, OH | Dialysis facility |
Promedica Toledo Hospital | Toledo, OH | Hospital |
Mercy St Vincent Medical Center | Toledo, OH | Hospital |
Emma L Bixby Medical Center | Adrian, MI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Toledo Clinic Incorporated | 5698673382 | 248 |
News Archive
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.
PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled "Methods and systems for dynamic gene expression profiling", with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011.
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
Hurricanes Katrina and Rita may be responsible for up to half of the stillbirths in the areas hardest hit by the storms, according to a new study co-authored by Ian Breunig, PhD, a postdoctoral fellow in the Department of Pharmaceutical Health Services Research (PHSR) and the Center for Innovative Pharmacy Solutions in the Department of Pharmacy Practice and Science (PPS) at the University of Maryland School of Pharmacy.
› Verified 5 days ago
Entity Name | Toledo Clinic Incorporated |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1144217894 PECOS PAC ID: 5698673382 Enrollment ID: O20031219000210 |
News Archive
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.
PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled "Methods and systems for dynamic gene expression profiling", with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011.
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
Hurricanes Katrina and Rita may be responsible for up to half of the stillbirths in the areas hardest hit by the storms, according to a new study co-authored by Ian Breunig, PhD, a postdoctoral fellow in the Department of Pharmaceutical Health Services Research (PHSR) and the Center for Innovative Pharmacy Solutions in the Department of Pharmacy Practice and Science (PPS) at the University of Maryland School of Pharmacy.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Mariano H Demiguel, MD 4235 Secor Rd, Toledo, OH 43623-4231 Ph: (419) 479-5529 | Dr Mariano H Demiguel, MD 4235 Secor Rd, Toledo, OH 43623-4231 Ph: (419) 479-5529 |
News Archive
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.
PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled "Methods and systems for dynamic gene expression profiling", with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011.
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
Hurricanes Katrina and Rita may be responsible for up to half of the stillbirths in the areas hardest hit by the storms, according to a new study co-authored by Ian Breunig, PhD, a postdoctoral fellow in the Department of Pharmaceutical Health Services Research (PHSR) and the Center for Innovative Pharmacy Solutions in the Department of Pharmacy Practice and Science (PPS) at the University of Maryland School of Pharmacy.
› Verified 5 days ago
Dr. Mani Khorsand Askari, M.D, FACP Nephrology Medicare: Medicare Enrolled Practice Location: 3000 Arlington Ave Ofc, Toledo, OH 43614 Phone: 419-383-6821 Fax: 419-383-6180 | |
Hoda Shabpiray, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3125 Transverse Dr, Toledo, OH 43614 Phone: 419-383-3627 Fax: 419-383-2021 | |
Theodore J. Ware, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2409 Cherry St, Suite 207, Toledo, OH 43608 Phone: 419-251-4696 Fax: 419-251-3572 | |
Muhammad Rizwan Faisal, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2142 N Cove Blvd, Toledo, OH 43606 Phone: 419-291-1111 | |
Drew Randall Oostra, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2109 Hughes Dr Ste 450, Toledo, OH 43606 Phone: 419-291-2003 Fax: 419-479-6977 | |
Dr. Caitlyn Marie Hollingshead, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3000 Arlington Ave # Ms 1201, Toledo, OH 43614 Phone: 419-383-3780 Fax: 419-383-2021 | |
Naeem A Lughmani, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4235 Secor Rd, Toledo, OH 43623 Phone: 419-479-5392 |